This study addresses Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic disorder characterized by extreme fragility of the skin and mucous membranes. The objective is to explore the clinical, genetic, and psychosocial implications for patients with RDEB, with an emphasis on emerging therapies such as gene and biotechnological interventions. Using a qualitative methodology and a literature review from reputable scientific databases, the study will analyze the effectiveness of these new therapies and their impact on patients’ quality of life. The main expected outcomes include validating the new therapies and formulating guidelines to improve the management of RDEB. It is concluded that emerging therapeutic approaches have the potential to transform the prognosis of RDEB, although further studies are necessary to consolidate these strategies.